Cargando…

Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study

Background: There are various differences in response to different antipsychotics and antioxidant defense systems (ADS) by sex. Previous studies have shown that several ADS enzymes are closely related to the treatment response of patients with antipsychotics-naïve first-episode (ANFE) schizophrenia....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Haixia, Liu, Hua, Jiang, Shuling, Su, Lei, Lu, Yi, Chen, Zhenli, Li, Xiaojing, Li, Xirong, Wang, Xuemei, Xiu, Meihong, Zhang, Xiangyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881066/ https://www.ncbi.nlm.nih.gov/pubmed/34766896 http://dx.doi.org/10.2174/1570159X19666211111123918

Ejemplares similares

Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
por: Guan, Xiaoni, et al.
Publicado: (2022)

Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone
por: Gao, Zhiyong, et al.
Publicado: (2023)

Plasma Lysophosphatidylcholine and Lysophosphatidylethanolamine Levels Were Associated With the Therapeutic Response to Olanzapine in Female Antipsychotics-naïve First-episode Patients With Schizophrenia
por: Liu, Jiahong, et al.
Publicado: (2021)

Association between Changes in Total Antioxidant Levels and Clinical Symptom Improvement in Patients with Antipsychotic-Naïve First-Episode Schizophrenia after 3 Months of Risperidone Monotherapy
por: Wang, Keqiang, et al.
Publicado: (2022)

Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study
por: Lang, Xiaoe, et al.
Publicado: (2023)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study
por: Liu, Jiahong, et al.
Publicado: (2021)

Tardive Dyskinesia Following Low-Dose Risperidone
por: Rokon, Ahmad E, et al.
Publicado: (2022)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Agarwal, A.K., et al.
Publicado: (1998)

Superoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study
por: Wu, Zhiwei, et al.
Publicado: (2021)

Neuronavigated Repetitive Transcranial Stimulation Improves Neurocognitive Functioning in Veterans with Schizophrenia: A Possible Role of BDNF Polymorphism
por: Su, Xiuru, et al.
Publicado: (2023)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

COMPARATIVE EFFICACY OF CENTBUTINDOLE & RISPERIDONE IN SCHIZOPHRENIA
por: Chandra, R., et al.
Publicado: (2002)

Risperidone Associated Paralytic Ileus in Schizophrenia
por: Ramamourthy, Parthasarathy, et al.
Publicado: (2013)

Alterations in innate immune defense distinguish first-episode schizophrenia patients from healthy controls
por: Chen, Song, et al.
Publicado: (2022)

The inconsistent mediating effect of catechol O methyl transferase Val(158)Met polymorphism on the sex difference of cognitive impairment in schizophrenia patients
por: Xu, Hang, et al.
Publicado: (2022)

Clinical utility of the risperidone formulations in the management of schizophrenia
por: Madaan, Vishal, et al.
Publicado: (2011)

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study
por: Zhao, Lei, et al.
Publicado: (2023)

Correlation of hair risperidone concentration and serum level among patients with schizophrenia
por: Sun, Xiujia, et al.
Publicado: (2019)

Unmasking of Myasthenia Gravis After Introduction of Oral Risperidone in a Schizophrenic Saudi Male: A Case Report
por: Abualkhair, Lamees, et al.
Publicado: (2021)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Liu-Seifert, Hong, et al.
Publicado: (2009)

Schizoaffective Disorder That Is Induced By Electrical Voltage That Is Treated with Risperidone
por: Fadhilah, Ihsan, et al.
Publicado: (2019)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Methylome-wide association study of different responses to risperidone in schizophrenia
por: Du, Huihui, et al.
Publicado: (2022)

Glucose metabolism, hippocampal subfields and cognition in first-episode and never-treated schizophrenia
por: Xiu, Meihong, et al.
Publicado: (2023)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

Influence of EGR3 Transfection on Imaging and Behavior in Rats and Therapeutic Effect of Risperidone in Schizophrenia Model
por: Li, Guangfei, et al.
Publicado: (2020)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia
por: Qiu, Yuying, et al.
Publicado: (2023)

Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
por: Bishop, Jeffrey R, et al.
Publicado: (2008)

REEMERGENCE OF POSITIVE SYMPTOMS OF SCHIZOPHRENIA DURING THE COURSE OF TREATMENT WITH RISPERIDONE
por: Bajaj, Priya, et al.
Publicado: (1999)

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
por: Shoja Shafti, Saeed, et al.
Publicado: (2014)

Risperidone improves interpersonal perception and executive function in patients with schizophrenia
por: Zhou, Zhenhe, et al.
Publicado: (2016)

Risperidone Abruption-Induced Tardive Dyskinesia in a Six-Year-Old Male Patient With Known Autism and Attention Deficit Hyperactivity Disorder: A Case Report
por: Alhamoud, Abdullah H, et al.
Publicado: (2022)

Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone
por: Taurines, R., et al.
Publicado: (2022)

Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study
por: Chen, Xiaofang, et al.
Publicado: (2023)

Genetic polymorphisms of BDNF on cognitive functions in drug-naive first episode patients with schizophrenia
por: Su, Xiuru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hsh5sjndoki76cheruumtasd5q